TheodoreErichSpiroMD

PubMed

• 79 citations
  Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
  Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Colleen Peluso, Theodore E. Spiro, Yoriko De Sanctis, Elliot S. Barnathan, Gary E. Raskob> ;TH Open. 2020 Mar 13
• 16 citations
  Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
  Jeffrey I. Weitz, Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Yoriko De Sanctis, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Domenick Argenti, Haitao Yang, John ...> ;Thrombosis and Haemostasis. 2020 Jan 23
• 172 citations
  Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
  Alex C. Spyropoulos, Walter Ageno, Gregory W. Albers, C. Gregory Elliott, Jonathan L. Halperin, William R. Hiatt, Gregory A. Maynard, P. Gabriel Steg, Jeffrey I. Weitz...> ;The New England Journal of Medicine. 2018 Aug 26
• Rivaroxaban for Thromboprophylaxis Among Patients Recently Hospitalized for Acute Infectious Diseases: A Subgroup Analysis of the MAGELLAN Study
  Robert D McBane, Lloyd Haskell, Theodore E Spiro> ;Journal of Thrombosis and Haemostasis.
• 47 citations
  Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure
  Alexandre Mebazaa, Theodore E. Spiro, Harry R. Büller, Lloyd Haskell, Dayi Hu, Russell D. Hull, Geno J. Merli, Sebastian W. Schellong, Alex C. Spyropoulos, Victor F. T...> ;Circulation. 2014 Jul 29
• 46 citations
  Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.
  Edelgard Lindhoff-Last, Jack Ansell, Theodore E. Spiro, Meyer Michel Samama> ;Annals of Medicine. 2013 Aug 16
• 112 citations
  Laboratory assessment of rivaroxaban: a review
  Meyer Michel Samama, Genevieve Contant, Theodore E. Spiro, Elisabeth Perzborn, Léna Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde, Jean Luc Martinoli> ;Thrombosis Journal. 2013 Jul 3
• 195 citations
  Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
  Cohen, A. T., Spiro, T. E., Spyropoulos, A. C.> ;The New England journal of medicine. 2013 May 17
• 230 citations
  Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
  Alexander T Cohen, Theodore E Spiro, Harry R Büller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex C Spyropoulos, Vict...> ;The New England Journal of Medicine. 2013 Feb 7
• 74 citations
  Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.
  Meyer Michel Samama, Genevieve Contant, Theodore E. Spiro, Elisabeth Perzborn, Léna Le Flem, Céline Guinet, Yves Gourmelin, Jean Luc Martinoli> ;Clinical and Applied Thrombosis/hemostasis. 2012 Mar 2
• 199 citations
  Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
  Meyer Michel Samama, Genevieve Contant, Theodore E. Spiro, Elisabeth Perzborn, Céline Guinet, Yves Gourmelin, Léna Le Flem, Gabriele Rohde, Jean Luc Martinoli> ;Thrombosis and Haemostasis. 2011 Dec 21
• 94 citations
  Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
  Alexander T. Cohen, Theodore E. Spiro, Harry R. Büller, Lloyd Haskell, Dayi Hu, Russell D. Hull, Alexandre Mebazaa, Geno J. Merli, Sebastian Schellong, Alex C. Spyropo...> ;Journal of Thrombosis and Thrombolysis. 2011 Feb 27
• 129 citations
  Assays for measuring rivaroxaban: their suitability and limitations.
  Edelgard Lindhoff-Last, Meyer Michel Samama, Thomas L. Ortel, Jeffrey I. Weitz, Theodore E. Spiro> ;Therapeutic Drug Monitoring. 2010 Dec 1
• 189 citations
  Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
  Theodore E. Spiro, Richard J. Friedman, Thomas L. Whitsett, Gerhard J. Johnson, Geoffrey A. Gardiner, Glenn C. Landon, Maurice Jove> ;The Journal of Bone and Joint Surgery. American Volume. 2001 Mar 1
• 270 citations
  Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
  Geno Merli, Theodore E. Spiro, Carl-Gustav Olsson, Ulrich Abildgaard, Bruce L. Davidson, Amiram Eldor, Darlene Elias, Andrew P. Grigg, Dominique Musset, George M. Rodg...> ;Annals of Internal Medicine. 2001 Feb 6
• 15 citations
  ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN SUPPRESSES PROTHROMBIN ACTIVATION MORE EFFECTIVELY THAN UNFRACTIONATED HEPARIN IN PATIENTS TREATED FOR VENOUS THROMBOEMBOLISM
  Alan B. M. Grosset, Theodore E. Spiro, Julia Beynon, George M. Rodgers> ;Thrombosis Research. 1997 Jun 1
• 51 citations
  Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.
  Clifford W. Colwell, Theodore E. Spiro> ;Clinical Orthopaedics and Related Research. 1995 Oct 1
• 8 citations
  Chemotherapeutic Sensitivity of Normal and Leukemic Hematopoietic Progenitor Cells to N-[4-(9-Acrldinylamlno)-3-methoxyphenyl]-methanesulfonamlde, a New Anticancer Agent
  Theodore E. Spiro, Mirellle Socquet, Alain Deiforge, Pierre Stryckmans> ;Journal of the National Cancer Institute. 1981 Apr 1
• 2 citations
  A study of street heroin lots for the presence of the hepatitis B surface antigen
  Theodore E. Spiro, Russell Jaffe, Paul V. Holland> ;Drug and Alcohol Dependence. 1978 Nov 1
• Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin a...
  Fitzgerald, R. H., Spiro, T. E., Trowbridge, A. A., Gardiner, G. A., Whitsett, T. L., O'Connell, M. B., Ohar, J. A., Young, T. R.> ;J Bone Joint Surg Am. 2001 Jun
• Join now to see all

Abstracts/Posters

• Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial
  Theodore E. Spiro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial
  Theodore E. Spiro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies
  Theodore E. Spiro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magell...
  Theodore E. Spiro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all